SciBase Holding AB (publ)

SciBase is a global medical technology company specializing in the early detection and prevention of skin disorders. Headquartered in Stockholm, Sweden, the company's mission is to ensure proactive skin health management and early detection of skin cancer and other skin conditions, thereby minimizing patient suffering and empowering clinicians to improve and save lives.

SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines artificial intelligence (AI) and advanced Electrical Impedance Spectroscopy (EIS) technology to enhance diagnostic accuracy. The Nevisense platform addresses melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. Its product line also includes Nevisense Go, a handheld and portable device primarily used for skin barrier assessment in research and industrial applications. Nevisense is FDA-approved for melanoma detection in the United States and MDR-approved for skin cancer detection in Europe.

Built on over 20 years of research from the Karolinska Institute, SciBase is positioned as a leader in dermatological advancements. Recent developments include reaching a milestone of over 400,000 Nevisense tests sold and receiving FDA approval in April 2026 to expand Nevisense labeling to include other healthcare professionals beyond dermatologists in the U.S. The company also published its Annual Report for 2025 in April 2026 and expanded its collaboration with Castle Biosciences in November 2025, which included a SEK 20 million loan facility. SciBase is currently the sole company with approved products utilizing EIS and AI for skin cancer and skin barrier function assessment, and Nevisense remains the only point-of-care product available for melanoma detection in the U.S. Pia Renaudin serves as CEO, and Michael Colérus is the CFO.